Concomitant use of glucocorticoids in patients with metastatic castration resistant prostate cancer (mCRPC) treated with oral therapies.
Bibliographic record
Abstract
e16577 Background: This study aims to assess whether there was an association of concomitant GC usage with dose reduction in patients treated with abiraterone acetate (AA) or enzalutamide (ENZ). Methods: The MarketScan databases were used to conduct a retrospective analysis, in which mCRPC patients initiated on AA or ENZ (index date) between 10/2012 and 12/2014 with ≥ 6 months of continuous eligibility prior to index date and ≥ 1 PC diagnosis during the period of continuous eligibility were included. Patients were followed until either 12 months of follow-up, loss to follow-up, or end of data. Multivariate Cox proportional hazards models were used to assess whether there was an association between concomitant GC use and the risk of dose reduction in oral PC therapies – AA and ENZ. Relative dose intensity (RDI) was used to measure dose reduction, calculated as the ratio of the delivered dose intensity (i.e., dose per unit of time, calculated by dividing the total delivered dose by the time period over which the total dose was measured) to the standard dose intensity as recommended in the package insert for AA or ENZ. Results: Respectively, 2,591 and 807 patients initiated on AA or ENZ and formed the study population. During follow-up, GCs were used in 91% of AA patients and 32% of ENZ patients.. Cox models showed that use of GC was associated with a lower risk of dose reduction (hazard ratio [HR] = 0.49, and 0.44 [RDI ≤ 0.85, ≤ 0.80], respectively [all p < 0.01]). Similar results were obtained using Cox models stratified by AA or ENZ (HR = 0.39, 0.33, 0.50 and 0.54 for AA [RDI ≤ 0.85, 0.80] and ENZ [RDI ≤ 0.85, 0.80], respectively). Conclusions: GC usage was associated with a lower risk of dose reduction in oral mCRPC therapies for patients initiated on AA or ENZ. Additional research is needed to understand the protective effect of GC usage on dose reduction in patients receiving the oral mCRPC therapies in this study.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.002 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".